B. Lovász

发表

Low incidence of venous thromboembolism in inflammatory bowel diseases: prevalence and predictors from a population-based inception cohort

P. Lakatos, K. Gecse, L. Lakatos, 2015, Scandinavian journal of gastroenterology.

Quality of care indicators in inflammatory bowel disease in a tertiary referral center with open access and objective assessment policies.

A. Bitton, P. Lakatos, W. Afif, 2018, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

Therapeutic preferences and outcomes in newly diagnosed patients with Crohn’s diseases in the biological era in Hungary: a nationwide study based on the National Health Insurance Fund database

P. Lakatos, Z. Végh, P. Golovics, 2018, BMC Gastroenterology.

Nationwide prevalence and drug treatment practices of inflammatory bowel diseases in Hungary: A population-based study based on the National Health Insurance Fund database.

P. Lakatos, K. Gecse, Z. Végh, 2016, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

Risk Matrix for Prediction of Disease Progression in a Referral Cohort of Patients with Crohn's Disease.

M. Papp, P. Lakatos, Z. Shums, 2015, Journal of Crohn's & colitis.

Inflammatory bowel disease course in Crohn's disease: is the natural history changing?

P. Lakatos, M. Mandel, P. Golovics, 2014, World journal of gastroenterology.

Levels of anti-double-strained DNA but not antinuclear antibodies are associated with treatment efficacy and adverse outcomes in Crohn's disease patients treated with anti-TNFα.

K. Farkas, T. Molnár, M. Papp, 2013, Journal of gastrointestinal and liver diseases : JGLD.

First prospective European study for the feasibility and safety of magnetically controlled capsule endoscopy in gastric mucosal abnormalities

L. Madácsy, A. Rosztóczy, B. Lovász, 2022, World journal of gastroenterology.

Tuberculin Skin Test and Quantiferon in BCG Vaccinated, Immunosuppressed Patients with Moderate-to-Severe Inflammatory Bowel Disease.

K. Farkas, T. Molnár, P. Lakatos, 2015, Journal of gastrointestinal and liver diseases : JGLD.

Optimizing Patient Management in Crohn's Disease in a Tertiary Referral Center: the Impact of Fast-Track MRI on Patient Management and Outcomes.

P. Lakatos, G. Rudas, Z. Végh, 2018, Journal of gastrointestinal and liver diseases : JGLD.

Work disability and productivity loss in patients with inflammatory bowel diseases in Hungary in the era of biologics

K. Farkas, T. Molnár, P. Lakatos, 2014, The European Journal of Health Economics.

Erratum to: Work disability and productivity loss in patients with inflammatory bowel diseases in Hungary in the era of biologics

K. Farkas, T. Molnár, P. Lakatos, 2014, The European Journal of Health Economics.

Efficacy and Safety of the Biosimilar Infliximab CT-P13 Treatment in Inflammatory Bowel Diseases: A Prospective, Multicentre, Nationwide Cohort.

K. Farkas, F. Nagy, T. Molnár, 2016, Journal of Crohn's & colitis.

New trends in inflammatory bowel disease epidemiology and disease course in Eastern Europe.

P. Lakatos, Z. Végh, P. Golovics, 2013, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

Association of extraintestinal manifestations and anaemia with disease outcomes in patients with inflammatory bowel disease

G. Rogler, S. Vavricka, P. Lakatos, 2016, Scandinavian journal of gastroenterology.

Does Hospitalization Predict the Disease Course in Ulcerative Colitis? Prevalence and Predictors of Hospitalization and Re-Hospitalization in Ulcerative Colitis in a Population-based Inception Cohort (2000-2012).

P. Lakatos, M. Mandel, L. Lakatos, 2015, Journal of gastrointestinal and liver diseases : JGLD.

Prevalence and predictors of hospitalization in Crohn's disease in a prospective population-based inception cohort from 2000-2012.

P. Lakatos, M. Mandel, L. Lakatos, 2015, World journal of gastroenterology.

Decreasing trends in hospitalizations during anti-TNF therapy are associated with time to anti-TNF therapy: Results from two referral centres.

K. Farkas, T. Molnár, P. Lakatos, 2014, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

The risk of lymphoma and immunomodulators in patients with inflammatory bowel diseases: results from a population-based cohort in Eastern Europe.

P. Lakatos, M. Szathmári, M. Mandel, 2013, Journal of Crohn's & colitis.

Is Current Smoking Still an Important Environmental Factor in Inflammatory Bowel Diseases? Results from a Population-based Incident Cohort

P. Lakatos, M. Szathmári, M. Mandel, 2013, Inflammatory bowel diseases.

Early clinical remission and normalisation of CRP are the strongest predictors of efficacy, mucosal healing and dose escalation during the first year of adalimumab therapy in Crohn’s disease

G. Veres, K. Farkas, F. Nagy, 2011, Alimentary pharmacology & therapeutics.

[Predictors of efficacy, mucosal healing and dose intensification during the first year of adalimumab therapy in patients with luminal and fistulizing Crohn's disease. National data from Hungary].

G. Veres, K. Farkas, F. Nagy, 2011, Orvosi Hetilap.

Prediction of Short- and Medium-term Efficacy of Biosimilar Infliximab Therapy. Do Trough Levels and Antidrug Antibody Levels or Clinical And Biochemical Markers Play the More Important Role?

K. Farkas, T. Molnár, M. Papp, 2016, Journal of Crohn's & colitis.

Efficacy of Infliximab Biosimilar CT-P13 Induction Therapy on Mucosal Healing in Ulcerative Colitis.

K. Farkas, F. Nagy, T. Molnár, 2016, Journal of Crohn's & colitis.

Antibody and cell-mediated immune response to whole virion and split virion influenza vaccine in patients with inflammatory bowel disease on maintenance immunosuppressive and biological therapy

K. Farkas, F. Nagy, T. Wittmann, 2014, Scandinavian Journal of Gastroenterology.

Su1331 Is Hospitalization Predicting the Disease Course in Crohn's Disease? Prevalence and Predictors of Hospitalization and Re-Hospitalization in Crohn's Disease in a Population Based Inception Cohort Between 2000-2012

P. Lakatos, M. Mandel, L. Lakatos, 2014 .

Long-term Efficacy, Safety, and Immunogenicity of Biosimilar Infliximab After One Year in a Prospective Nationwide Cohort

K. Farkas, F. Nagy, T. Molnár, 2017, Inflammatory bowel diseases.

Network meta-analysis of prophylactic pancreatic stents and non-steroidal anti-inflammatory drugs in the prevention of moderate-to-severe post-ERCP pancreatitis.

P. Novak, L. Madácsy, Z. Dubravcsik, 2021, Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.].

Perceived Risks Contra Benefits of Using Biosimilar Drugs in Ulcerative Colitis: Discrete Choice Experiment among Gastroenterologists.

M. Péntek, P. Baji, V. Brodszky, 2016, Value in health regional issues.

[The role of fecal calprotectin in the diagnosis and treatment of gastrointestinal diseases].

P. Lakatos, B. Lovász, Á. Iliás, 2019, Orvosi hetilap.

Autoregressive cross-lagged models of IMPACT-III and Pediatric Crohn's Disease Activity Indexes during one year infliximab therapy in pediatric patients with Crohn's disease.

G. Veres, M. Papp, P. Lakatos, 2014, Journal of Crohn's & colitis.

Incidence rates and disease course of paediatric inflammatory bowel diseases in Western Hungary between 1977 and 2011.

G. Veres, P. Lakatos, M. Mandel, 2014, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

Has There Been a Change in the Natural History of Crohn's Disease? Surgical Rates and Medical Management in a Population-Based Inception Cohort from Western Hungary Between 1977–2009

G. Veres, P. Lakatos, M. Szathmári, 2012, The American Journal of Gastroenterology.

Is early limited surgery associated with a more benign disease course in Crohn's disease?

G. Veres, P. Lakatos, M. Mandel, 2013, World journal of gastroenterology.

Risk of colorectal cancer in Crohn's disease patients with colonic involvement and stenosing disease in a population-based cohort from Hungary.

P. Lakatos, M. Mandel, L. Lakatos, 2013, Journal of gastrointestinal and liver diseases : JGLD.

P623 Therapeutic preferences and outcomes in newly diagnosed patient with inflammatory bowel diseases in the biological era in Hungary. A nationwide study based on the National Health Insurance Fund database.

P. Lakatos, K. Gecse, Z. Végh, 2017, Journal of Crohn's & colitis.

Evolution of disease phenotype in adult and pediatric onset Crohn's disease in a population-based cohort.

P. Lakatos, M. Mandel, L. Lakatos, 2013, World journal of gastroenterology.

Drug persistence and need for dose intensification to adalimumab therapy; the importance of therapeutic drug monitoring in inflammatory bowel diseases

K. Farkas, T. Molnár, P. Lakatos, 2017, BMC Gastroenterology.

[The effect of early immunosuppressive therapy on the rate of resections performed in patients with Chron's disease, in Veszprém county, Hungary, a population-based cohort study].

P. Lakatos, M. Szathmári, L. Lakatos, 2012, Orvosi hetilap.

Burden of Clostridium difficile infection between 2010 and 2013: Trends and outcomes from an academic center in Eastern Europe.

P. Lakatos, M. Szathmári, M. Mandel, 2015, World Journal of Gastroenterology.

Final Results on Immunogenicity Profile and Predictors of ADA Development of Biosimilar Infliximab During the First 12 Months of the Therapy: Results from a Prospective Nationwide Cohort

K. Farkas, T. Molnár, M. Papp, 2017 .

P592 Final results on immunogenicity profile and predictors of ADA development of biosimilar infliximab during the first 12 months of the therapy: results from a prospective nationwide cohort.

T. Molnár, M. Papp, P. Lakatos, 2017, Journal of Crohn's & colitis.

P331 Final results on efficacy and safety of biosimilar infliximab after one-year: results from a prospective nationwide cohort.

F. Nagy, T. Molnár, M. Papp, 2017, Journal of Crohn's & colitis.

Improved adenoma detection with linked color imaging technology compared to white-light colonoscopy

L. Madácsy, Z. Dubravcsik, B. Lovász, 2020, Scandinavian journal of gastroenterology.

Treatment preferences of originator versus biosimilar drugs in Crohn’s disease; discrete choice experiment among gastroenterologists

P. Lakatos, M. Péntek, P. Baji, 2016, Scandinavian journal of gastroenterology.

F. Nagy, M. Papp, P. Lakatos, 2015 .

K. Farkas, T. Molnár, M. Papp, 2015 .

A novel hybrid first-line therapy for H . pylori eradication : results of a pilot study

L. Lakatos, B. Lovász, Peter, 2019 .

Sa1156 Accelerated Treatment Strategy in Inflammatory Bowel Diseases; Is It Associated With a Change in the Disease Course?

K. Farkas, T. Molnár, M. Papp, 2015 .

Clinical efficacy, drug sustainability and serum drug levels in Crohn's disease patients treated with ustekinumab - A prospective, multicenter cohort from Hungary.

K. Farkas, T. Molnár, P. Sarlós, 2021, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

Comparison of the efficacy and safety of commercially available fixed ratio combinations of insulin degludec/liraglutide (IDegLira) and insulin glargine/lixisenatide (iGlarLixi) - a network meta-analysis.

Á. Tabák, V. Horváth, S. Mészáros, 2023, Canadian journal of diabetes.

Incidence rates and disease course of pediatric inflammatory bowel diseases in western Hungary between 1977 – 2011

G. Veres, P. Lakatos, M. Mandel, 2014 .

Quality of care indicators in inflammatory bowel disease in a tertiary referral center with open access and objective assessment policies.

A. Bitton, P. Lakatos, W. Afif, 2018, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

Efficacy and Safety of the Biosimilar Infliximab CT-P13 Treatment in Inflammatory Bowel Diseases: A Prospective, Multicentre, Nationwide Cohort.

K. Farkas, F. Nagy, T. Molnár, 2016, Journal of Crohn's & colitis.

Autoregressive cross-lagged models of IMPACT-III and Pediatric Crohn's Disease Activity Indexes during one year infliximab therapy in pediatric patients with Crohn's disease.

G. Veres, M. Papp, P. Lakatos, 2014, Journal of Crohn's & colitis.